Is Johnson & Johnson Stock a Buy?
Johnson & Johnson (NYSE: JNJ) has quietly emerged as a compelling turnaround story with its stock price rallying sharply in recent months and currently trading at a 52-week high. Compared to a frustrating last couple of years for investors, the latest results from the healthcare giant highlights rebounding growth and an improved earnings outlook.
Could the stock make a good addition to your portfolio today? Here's what you need to know.
There's a lot to like about Johnson & Johnson, a company recognized for its history of innovation and strong fundamentals. A major development in recent years was the 2023 spinoff of its consumer health division, which included brands like Tylenol and Band-Aid, with the creation of Kenvue as a fully independent company. Management made the restructuring decision in part to refocus the company's efforts on core strengths within pharmaceuticals and medical technologies. It appears the strategy is now paying off.
Source Fool.com
